These studies demonstrated that inhibition of ANXA2 provided a new regulatory tool on NF‐κB activity and supported the notion that the inhibition of ANXA2 may be a suitable anti‐cancer therapy (Wang et al., 2018). Here, ANXA2 is linked to cancer.